Vitamin B12 Longevity-Medicine Target Ranges: What Optimal Looks Like

Why the Standard Reference Range Misses the Mark

Most commercial labs report a B12 reference range of approximately 200 to 900 pg/mL, meaning any result above 200 pg/mL is stamped "normal." That cutoff was built to catch overt megaloblastic anemia, not to protect the nervous system or preserve long-term cognitive function. Patients can carry serum B12 levels of 250 or 300 pg/mL and still show measurable neurological damage.

The gap between "not deficient" and "optimal"

A 2013 systematic review published in JAMA Internal Medicine highlighted that neurological symptoms of B12 deficiency often appear at serum concentrations between 200 and 300 pg/mL, well within the conventional "normal" band. The authors concluded that the lower reference limit should be raised to at least 300 pg/mL for neurological protection alone [1].

Population data from the National Health and Nutrition Examination Survey (NHANES) found that roughly 6% of U.S. Adults under 60 and nearly 20% of adults over 60 had serum B12 below 300 pg/mL, despite most of those values technically clearing the lab flag threshold [2].

Where longevity medicine sets the bar

Longevity-medicine practitioners, including those following the framework used by the American College for Advancement in Medicine and functional-medicine training curricula, generally target serum total B12 between 600 and 1,000 pg/mL. At these concentrations, homocysteine tends to be well-controlled (ideally below 9 micromol/L), methylmalonic acid stays suppressed, and neurological tissue has an adequate reserve against the metabolic demands of methylation and myelin synthesis.

Levels above 1,000 pg/mL in the absence of supplementation deserve investigation because they may reflect hepatic disease, myeloproliferative disorders, or solid tumor activity rather than dietary adequacy.

How B12 Actually Works in the Body

Cobalamin is not a single compound. It is a family of cobalt-containing molecules that serve as cofactors for exactly two human enzymes: methionine synthase (which converts homocysteine to methionine) and methylmalonyl-CoA mutase (which processes odd-chain fatty acids and certain amino acids). Both reactions are required for neurological integrity and one-carbon metabolism.

Absorption: where most people lose

Dietary B12 is released from food proteins by gastric acid and pepsin, then bound to intrinsic factor secreted by gastric parietal cells, and finally absorbed in the terminal ileum. This process fails in four common clinical scenarios.

First, atrophic gastritis reduces both acid and intrinsic factor. The Framingham Offspring Study found that food-bound B12 malabsorption affected an estimated 10 to 30% of adults over 50, even without pernicious anemia [3]. Second, proton-pump inhibitors and H2 blockers suppress the acid step. A 2015 JAMA case-control study (N=25,956) found a 65% increased odds of B12 deficiency among people taking PPIs for two or more years (OR 1.65, 95% CI 1.58 to 1.73) [4]. Third, ileal disease or resection abolishes intrinsic factor-mediated uptake entirely. Fourth, metformin blocks the calcium-dependent ileal receptors for the intrinsic factor-B12 complex; this mechanism is distinct from acid suppression and is not fixed by gastric acid correction alone.

Transport and the active fraction

Once absorbed, B12 circulates bound to two proteins: haptocorrin (transcobalamin I) and transcobalamin II. Only the transcobalamin II fraction, called holotranscobalamin (holoTC), delivers B12 to tissues. HoloTC represents roughly 20 to 30% of total serum B12 but carries 100% of the biologically available cobalamin. A holoTC below 35 pmol/L reliably predicts tissue depletion before total B12 falls below the conventional cut-off [5].

Metformin and B12: A Relationship Every Prescriber Must Track

Metformin is the most widely prescribed glucose-lowering agent worldwide. It is also one of the most reproducible causes of B12 depletion in clinical practice. The relationship is dose-dependent and duration-dependent.

The evidence base

The UKPDS trial and subsequent analyses established that metformin reduces serum B12 in a meaningful proportion of users. A dedicated randomized trial by de Jager et al. (BMJ, 2010, N=390) found that metformin 850 mg three times daily for 4.3 years reduced serum B12 by a mean of 19% compared with placebo (P<0.001), and B12 levels fell below 150 pmol/L in 7.2% of the metformin group versus 0% in placebo [6]. A 2019 meta-analysis of 31 studies found a pooled prevalence of B12 deficiency of 29.4% among metformin users, compared with 2.4% in the general diabetic population not taking metformin [7].

Clinical implications for neuropathy attribution

Diabetic peripheral neuropathy and metformin-induced B12 deficiency neuropathy are clinically indistinguishable. Both cause length-dependent sensorimotor symptoms beginning in the feet. Correcting B12 deficiency can halt progression and, in some patients, partially reverse symptoms, but misattributing the neuropathy to diabetes alone will delay that correction. The American Diabetes Association's 2024 Standards of Care state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially those with peripheral neuropathy or anemia" [8].

Monitoring protocol for metformin users

Clinicians should obtain a baseline B12 before starting metformin or at first opportunity in established users. Repeat testing at 12-month intervals is reasonable. If total B12 falls below 400 pg/mL, supplementation should begin. If neurological symptoms are present, functional markers (methylmalonic acid, holotranscobalamin) should be checked regardless of the total B12 value.

Functional Markers: When Total B12 Is Not Enough

Serum total B12 reflects the sum of active and inactive fractions. Because haptocorrin (the inactive carrier) can remain elevated even when tissue delivery is impaired, total B12 may look normal while the cell is genuinely starved of cobalamin.

Methylmalonic acid (MMA)

MMA accumulates when methylmalonyl-CoA mutase is under-cofactored. Serum MMA above 0.4 micromol/L (or urine MMA above 3.6 micromol/mmol creatinine) indicates functional intracellular B12 deficiency with high specificity. The Tufts-led Framingham Heart Study analysis found that elevated MMA was present in roughly 25% of adults with serum B12 below 300 pg/mL, confirming that a large fraction of borderline-normal results represent true tissue deficiency [3].

MMA is less useful in patients with renal impairment because the kidneys clear MMA; elevated creatinine will inflate MMA values independently of B12 status.

Holotranscobalamin (holoTC)

HoloTC falls first in negative B12 balance, before total B12 or MMA change meaningfully. A 2003 Clinical Chemistry study found that holoTC below 35 pmol/L identified early B12 depletion with a sensitivity of 92% and specificity of 84%, outperforming total serum B12 at all conventional cutoffs [5]. Ordering holoTC is particularly useful in patients taking supplements who may have artificially elevated total B12.

Homocysteine

Elevated total homocysteine (tHcy above 10 to 15 micromol/L) reflects impaired methionine synthase activity, which depends on both B12 and folate as cofactors. Hyperhomocysteinemia is independently associated with cardiovascular disease and dementia. Correcting B12 deficiency lowers homocysteine by a mean of 2 to 4 micromol/L, an effect confirmed across multiple randomized trials [9]. Homocysteine should always be interpreted alongside folate status; if folate is also low, both need correction.

B12, Cognition, and Aging Brain Health

Neurological tissue depends on B12 for two processes that bear directly on cognitive aging. Myelin synthesis requires S-adenosylmethionine (SAM), which is regenerated from homocysteine through the B12-dependent methionine cycle. Odd-chain fatty acid clearance in central nervous system myelin sheaths depends on methylmalonyl-CoA mutase. When either pathway falters, demyelination can follow.

Observational evidence and trials

The Oxford Homocysteine and B-vitamins in Cognitive Impairment (VITACOG) trial randomized 168 adults with mild cognitive impairment to high-dose B-vitamins (folic acid 0.8 mg, B6 20 mg, B12 0.5 mg daily) or placebo for two years. MRI-measured brain atrophy rate in the B-vitamin group was 30% lower than placebo in the full cohort, and 53% lower in the subgroup with elevated baseline homocysteine (tHcy above 13 micromol/L) [10]. That is a large effect size from a low-cost intervention.

The benefit appears to be largest when initiated before significant neurodegeneration has occurred, which is precisely why longevity-medicine providers check B12 as part of routine screening rather than waiting for symptoms.

What the evidence does not yet show

No completed randomized trial has demonstrated that B12 supplementation reduces incident Alzheimer's disease or all-cause dementia in cognitively normal adults with adequate B12 status at baseline. The VITACOG data and supporting observational studies are compelling, but they apply most directly to individuals who are already B12-insufficient. Correcting deficiency is clearly warranted; prophylactic mega-dosing in replete patients remains a hypothesis rather than established practice.

Who Needs Screening and How Often

The table below summarizes the HealthRX tiered screening protocol, synthesized from ADA guidelines, endocrinology society statements, and published longevity-medicine frameworks.

| Risk Tier | Population | Recommended Test | Frequency | |---|---|---|---| | High | Metformin users, age >60, vegans, PPI >2 yr, prior gastric surgery | Total B12 + holoTC + MMA | Every 6 to 12 months | | Moderate | Age 50 to 60, vegetarians, frequent antacid use | Total B12 | Every 12 months | | Standard | Age <50, omnivore, no medications above | Total B12 | Every 2 to 3 years or at routine physical | | Symptomatic | Any age with neuropathy, glossitis, cognitive change | Total B12 + holoTC + MMA + homocysteine | Immediately, recheck 8 weeks after repletion |

Patients in the high-risk tier who show borderline-normal total B12 (200 to 400 pg/mL) should have MMA and holoTC checked before a supplementation decision is made, because both tests add clinical precision that total B12 alone cannot provide.

Repletion: Doses, Forms, and Expected Timelines

Getting B12 status from deficient to optimal is straightforward in most patients, but the route and dose depend on the underlying mechanism.

Oral vs. Intramuscular: which wins?

Passive diffusion across the gut mucosa absorbs roughly 1% of an oral dose without intrinsic factor. A 1,000 mcg oral tablet therefore delivers roughly 10 mcg by passive absorption, enough to bypass even complete intrinsic factor failure. A 2005 Cochrane systematic review found that high-dose oral cyanocobalamin (1,000 to 2,000 mcg daily) was as effective as intramuscular injection for normalizing serum B12 and MMA in patients with pernicious anemia and food-cobalamin malabsorption over a 90-day treatment period [11]. Intramuscular therapy remains preferred when rapid correction is needed (active neurological symptoms), patient adherence to daily oral dosing is doubtful, or malabsorption is severe and documented.

Cyanocobalamin vs. Methylcobalamin

Cyanocobalamin is the most stable and best-studied oral form. After absorption, it is converted to active methylcobalamin and adenosylcobalamin within cells. Methylcobalamin supplements are marketed as "active" forms but carry no proven clinical advantage over cyanocobalamin in people without the MTHFR C677T polymorphism. Sublingual methylcobalamin at 1,000 mcg daily is a reasonable choice for patients who prefer to avoid cyanide-containing compounds (the cyanide dose from cyanocobalamin is pharmacologically insignificant but some patients decline it on principle).

Expected response timeline

Serum B12 rises within days of high-dose oral supplementation. MMA typically normalizes within 4 to 8 weeks if the deficiency was the primary cause of elevation. Neurological symptoms can take months to partially resolve, and recovery is incomplete if axonal degeneration has been prolonged. A 2015 study in Neurology found that patients with subacute combined degeneration of the spinal cord showed neurological improvement in 60% of cases at six months with prompt B12 repletion, but only 30% achieved full functional recovery [12].

Recheck total B12 and MMA at 8 weeks after starting supplementation. If MMA remains elevated at 8 weeks, reassess absorption adequacy, check for renal impairment elevating MMA artificially, and confirm adherence.

Maintenance dose once replete

For patients in the longevity-medicine target range (600 to 1,000 pg/mL) who are supplementing: 250 to 500 mcg of cyanocobalamin or methylcobalamin daily maintains adequate serum concentrations in most adults. Higher doses (1,000 mcg daily) are appropriate for ongoing metformin use, any documented absorptive deficit, or strict plant-based diets.

Special Populations

Adults over 60

Gastric acid secretion declines with age. The result is food-cobalamin malabsorption without classic pernicious anemia and without antibodies to intrinsic factor. The Institute of Medicine (now National Academy of Medicine) recommended in its 1998 Dietary Reference Intakes report that adults over 50 obtain the majority of their B12 from crystalline (supplemental or fortified) form, specifically because crystalline B12 does not require gastric acid for release [13]. That recommendation remains current.

Vegans and strict vegetarians

Plant foods contain no B12. Algae and fermented plant products have been promoted as sources but their cobalamin is largely pseudovitamin B12 (inactive analogs). A 2020 meta-analysis (N=7,063) found that vegans had a 43% lower mean serum B12 than omnivores and a nearly six-fold higher prevalence of B12 deficiency by biochemical criteria [14]. Supplementation is non-negotiable, not optional, for this population.

Pregnancy

B12 deficiency during pregnancy raises the risk of neural tube defects, infant megaloblastic anemia, and neonatal neurological damage. The fetus actively concentrates B12 across the placenta; maternal serum B12 does not predict fetal adequacy when maternal levels are borderline. ACOG recommends that prenatal vitamins contain at least 2.6 mcg B12 daily, but women with documented deficiency require therapeutic doses well above that floor [15].

The single most actionable number from a B12 panel is not the raw serum value. It is whether methylmalonic acid has normalized on recheck at 8 weeks, because that confirms cellular-level repletion, not just a higher serum number.